Podcasts about relapsed

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of treating multiple myeloma, focusing on two challenging cases from the community. Joined by experts Marco Davila, MD PhD, from Roswell Park Comprehensive Cancer Center and Krina Patel, MD MSc, from MD Anderson Cancer Center, they discuss the nuances of treatment options for patients experiencing disease relapse post-transplant and disease progression while on maintenance therapy.   Key topics included: The importance of thorough workup and repeat cytogenetics in high-risk multiple myeloma patients The debate between CAR T-cell therapy and bispecific antibodies as treatment options Strategies for managing patients with comorbidities and the role of shared decision-making in treatment planning Insights into the side effects associated with CAR-T and bispecific therapies, including infection risks and neurological symptoms Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/  Join us as we explored the latest advancements in multiple myeloma treatment and the exciting potential for achieving long-term remission and even cure in select patient populations.   Don't forget to like, subscribe, and hit the notification bell for more insightful discussions on oncology! #MultipleMyeloma, #CARTtherapy, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers  

My website My Instagram

In this podcast episode, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, and Anthony Perissinotti, PharmD, BCOP, discuss the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy, including: A Brief Overview of BCMA in Multiple Myeloma Advances in BCMA-Targeted Agents in Progressing Myeloma Selection of BCMA-Directed Therapies for Early Relapse MM Operational Challenges Faced by Oncology Pharmacists Regarding the Incorporation of BCMA-Targeted Agents in Practice Identifying and Managing Adverse Events Associated With BCMA-Directed Agents Presenters:  Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP Clinical Oncology Pharmacy Manager Atrium Health Levine Cancer Institute Charlotte, North Carolina Anthony Perissinotti, PharmD, BCOP Hematology Clinical Pharmacist Specialist University of Michigan Ann Arbor, Michigan Link to full program:https://bit.ly/4gCsgXt Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EXN865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.The MoD Squad in Multiple Myeloma: CELMoDs as New Partners for Innovative Sequential Care in Relapsed/Refractory Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EXN865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.The MoD Squad in Multiple Myeloma: CELMoDs as New Partners for Innovative Sequential Care in Relapsed/Refractory Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EXN865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.The MoD Squad in Multiple Myeloma: CELMoDs as New Partners for Innovative Sequential Care in Relapsed/Refractory Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EXN865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.The MoD Squad in Multiple Myeloma: CELMoDs as New Partners for Innovative Sequential Care in Relapsed/Refractory Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we discussed in Episode 155. If you have not done so already, definitely listen to that episode as we build on the topics discussed here today!Content: - What are options after steroids?- How to counsel patients on options? - Is there a correct way to sequence available options? ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.

In this episode, Sathiya sits down with Zach, a DeepClean graduate, to discuss his journey from a lifelong struggle with pornography to lasting recovery and deeper personal growth. Zach shares how accidental exposure in childhood led to years of secrecy, shame, and repeated relapses despite pursuing counseling, accountability, and 12-step recovery. He reflects on the difficult process of rebuilding trust in his marriage, confronting the fear of being fully known, and recognizing that true recovery involves transformation of the heart, not just behavior change. Together, they explore key shifts that accelerated Zach's progress, including understanding the beliefs beneath addictive behaviors, addressing unmet emotional needs, and developing greater emotional awareness. The conversation highlights practical tools such as journaling, breathwork, and honest connection with God, as well as the role these practices have played in strengthening Zach's relationships, faith, and confidence as he prepares to become a father. Zach also shares how learning to identify lies, embrace vulnerability, and take consistent action helped him achieve nearly 10 months of freedom and build a healthier, more intentional life.   SATHIYA'S RESOURCES: Free Recovery Book (The Last Relapse) Join the brotherhood (DeepClean Inner Circle) Live Training To Quit Porn For Good Timestamps 00:00 – Meet Zach: Marriage, fatherhood on the horizon, and his background 01:01 – Early exposure to pornography and the beginning of a 20-year struggle 03:04 – The podcast insight that changed everything: freedom and character formation 03:38 – Coming clean to his wife and the impact on their marriage 08:03 – Finding support through friends, church community, and accountability 08:38 – Exploring DeepClean and taking the next step 09:09 – Previous recovery attempts: therapy, 12-step groups, and phone restrictions 10:16 – Why willpower and understanding the “why” weren't enough 11:23 – The belief shift that transformed his recovery journey 13:04 – How journaling uncovered hidden stress, anxiety, and overwhelm 13:38 – Using breathwork to regulate emotions and reconnect with himself 14:09 – Meeting emotional needs through connection with God 14:39 – Repenting of underlying beliefs, not just behaviors 16:17 – Integrating faith into breathwork and daily emotional health 18:31 – Replacing feelings of rejection with God's truth and love 21:14 – Processing anxiety, intrusive thoughts, and fear of failure 22:49 – How intentionality transformed friendships and relationships 24:01 – Preparing for fatherhood while overcoming insecurity and fear 26:10 – Applying recovery skills after the program ended 27:13 – Learning emotional skills he never developed growing up 27:47 – Celebrating 10 months free from pornography 30:32 – Advice for men considering their next recovery step 31:39 – Why addiction recovery requires guidance, structure, and support

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of relapsed refractory acute myeloid leukemia (AML) with expert guest Dr. Joshua Zeidner, Chief of Leukemia Research at the University of North Carolina. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore two challenging cases: Revumenib (menin inhibitor) demonstrated an overall response rate of ~63% in heavily pre-treated KMT2A rearrangement-positive AML patients based on the AUGMENT-101 study, with QTc prolongation and CYP3A4 drug interactions as key monitoring considerations. FLT3 inhibitors like gilteritinib and quizartinib play an important role in MRD-positive FLT3 ITD/NPM1-mutated AML post-transplant, with the MORPHO trial supporting gilteritinib as maintenance therapy.  Menin inhibitors may have a broader role in high-risk AML including NPM1-mutated disease, and re-evaluating mutational profiles at relapse is critical for optimal treatment selection.  Careful monitoring of side effect profiles, drug interactions, and MRD status is essential when navigating targeted therapy decisions in relapsed refractory AML. Throughout the episode, we discuss key practical points, including the importance of monitoring for QTc prolongation and the impact of drug interactions with CYP3A4 inhibitors. Tune in for an informative discussion that sheds light on the latest advancements in targeted therapies for AML and the evolving landscape of treatment options. Don't forget to like, subscribe, and check out our other episodes in the challenging case series, treatment algorithms, and conference highlights! #AcuteMyeloidLeukemia, #MeninInhibitor, #FLT3Inhibitor, #Hematology, #OncologyBrothers

Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.

David Shulman, MD, joins us on OsteoBites to discuss the newly opened phase 1/2 study to evaluate LNTH-2403, a LRRC15-targeted radiopharmaceutical, in patients with relapsed/refractory osteosarcoma.For many years, LRRC15 has been known to be an important target in osteosarcoma. A prior study showed a strong signal of activity of an LRRC15-targeted therapy in osteosarcoma; however, the development of the agent was not pursued. There is now a novel LRRC15-targeting radiopharmaceutical that has entered clinical trials for patients with osteosarcoma, and Dr. Shulman will provide an overview of this newly opened trial.Dr. David Shulman is a Pediatric Oncologist and clinical/translational researcher at Dana-Farber Cancer Institute, where he also serves as an Assistant Professor of Pediatrics at Harvard Medical School. As the Director of the DFCI AYA Sarcoma Program, he focuses his clinical practice on the specialized care of adolescents and young adults (AYA) diagnosed with sarcomas. His research program, which has received support from the NIH and Harvard Catalyst, is dedicated to improving patient outcomes through the investigation of novel therapeutic approaches and the utility of circulating tumor DNA (ctDNA) as a clinical biomarker. He leads a national liquid biopsy study for patients with Ewing sarcoma and osteosarcoma, known as the LEOPARD study.

In this episode, hear Doris K. Hansen, MD, discuss the management of relapsed/refractory multiple myeloma with bispecific antibodies including: Practical differences among approved bispecific antibodies Toxicity profiles of approved bispecific antibodies When to refer patients for evaluation for immunotherapies Considerations for sequencing bispecific antibodies in the relapsed/refractory setting New findings with combination regimens with bispecific antibodies Program faculty: Doris K. Hansen, MD Assistant Member, Blood and Marrow Transplant and Cellular Immunotherapy H. Lee Moffitt Cancer Center & Research Institute Assistant Professor University of South Florida Morsani College of Medicine Tampa, Florida Link to program page:https://bit.ly/4nufxr2 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In today's episode, we welcomed Luhua (Michael) Wang, MD, to discuss the implications of the full FDA approval of brexucabtagene autoleucel (Tecartus; brexu-cel) for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL). Dr Wang is a professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine, as well as a professor in the Department of Stem Cell Transplantation at The University of Texas MD Anderson Cancer Center in Houston.On April 2, 2026, the FDA granted traditional approval to brexu-cel based on data from the phase 2 ZUMA-2 trial (cohorts 1 and 2, NCT02601313; cohort 3, NCT04880434), with confirmatory data from cohort 3 showing that patients naive to a BTK inhibitor experienced an overall response rate (ORR) of 91% (95% CI, 82.5%-95.9%), a complete response (CR) rate of 79% (95% CI, 69.0%-87.1%), and a median duration of response (DOR) that was not reached (NR; 95% CI, 26.2 months-not evaluable).Dr Wang detailed the evolution of therapies in the MCL treatment paradigm, leading up to the approval of brexu-cel and the integration of CAR T-cell therapy. Along with highlighting the evolution of MCL management, Dr Wang explained how data from cohort 3 of ZUMA-2 add further context to the role of CAR T-cell therapy in the treatment paradigm and how it may affect treatment sequencing considerations.

In this episode, Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, discuss various strategies to optimize the use of bispecific antibodies in their practices for the treatment of R/R MM through patient monitoring, dosing in outpatient settings, and using tocilizumab and IVIG, among other management strategies.  Presenters:  Muhamed Baljevic, MD, FACP Associate Professor of Medicine Division of Hematology-Oncology Department of Medicine Director, Multiple Myeloma Program Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP) Co-Chair, Scientific Review Committee, VICC Disease Team Lead, Plasma Cell Dyscrasias and Lymphomas Vanderbilt-Ingram Cancer Center Vanderbilt University Medical Center Nashville, Tennessee Jonathan Ticku, MD Medical Oncologist and Hematologist GU Oncology Lead, Mayo Clinic Health System Assistant Professor of Oncology, Mayo Clinic La Crosse, Wisconsin Link to full program: https://bit.ly/4u0xH6q Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In today's episode, we spoke with Alissa Cooper, MD. Dr Cooper is a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Cooper discussed recent advances that have reshaped the treatment paradigm for small cell lung cancer (SCLC), particularly in the relapsed setting. She highlighted the FDA approval of tarlatamab-dlle (Imdelltra), a DLL3-targeting T-cell engager, as one of the most impactful developments in recent years. Despite this progress, Cooper emphasized that the frontline standard of care has remained largely unchanged, continuing to rely on platinum-based chemotherapy in combination with immunotherapy. She noted that, although ongoing clinical trials are exploring biomarker-driven strategies and novel combinations, a more personalized first-line approach has yet to be established.The conversation also explored real-world treatment sequencing and decision-making at the point of relapse. Cooper explained that, whenever feasible, oncologists aim to enroll patients in clinical trials or initiate treatment with tarlatamab. However, logistical barriers, including trial screening requirements and the need for monitored administration of T-cell engagers, can delay care. In cases of rapidly progressing disease, oncologists may instead turn to cytotoxic therapies such as lurbinectedin (Zepzelca) or use localized approaches like radiation to achieve faster disease control.The importance of multidisciplinary coordination was another key theme. Cooper underscored that SCLC management requires rapid collaboration among medical oncologists, radiation oncologists, pulmonologists, pathologists, and supportive care teams. Early involvement of palliative care is also critical, given the aggressive nature of the disease and high symptom burden.Additionally, she highlighted the essential role of oncology pharmacists, nursing teams, and structured patient education. Clear toxicity management protocols, dose-modification guidelines, and comprehensive patient education visits help ensure safe treatment delivery and empower patients to manage adverse effects.Looking ahead, Cooper described an “embarrassment of riches” in emerging therapies and targets under investigation. Beyond DLL3, novel approaches targeting markers such as SEZ6 and B7-H3, as well as next-generation antibody-drug conjugates and trispecific T-cell engagers, are showing early promise. However, key questions remain regarding biomarker selection, treatment sequencing, and real-world effectiveness, particularly for patients who would not meet clinical trial eligibility criteria.Finally, she emphasized that improving coordination between community and academic centers is essential to ensuring timely access to innovative therapies and clinical trials. Strengthening communication pathways and referral processes may help bridge gaps in care and improve outcomes for patients with this aggressive disease.

SO YOU RELAPSED, NOW WHAT? This episode of the Came to Believe Recovery Podcast explores the complex topic of relapse in recovery, addressing questions about recovery, relapse, and the spiritual and practical tools needed to navigate setbacks. Hosted by Monty Meyer and Tom Williams, it offers insights into maintaining sobriety, understanding relapse, and the importance of grace and community support.Can we recover or are we always in recovery? Can a recovered person relapse? Closing Song: God of Second Chances by Leroy Stoltzfus. Key Points ·         Relapse in Recovery: When It Happens and How to Respond·         Understanding Recovery and Relapse: A Spiritual Perspective #recovery #alcoholic #twelvesteps #wedorecover #addiction 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

Therapy, Maintenance, and Relapsed/Refractory SequencingThis week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part two, we cover three practical and rapidly evolving topics: the role of MRD testing in guiding treatment decisions, how to individualize maintenance therapy in 2026, and how to approach sequencing of CAR-T and bispecific therapies in the relapsed/refractory setting.In this week's show notes, we summarize the key thoughts about how our experts think about approach to their patients.If you have not already done so, be sure to check out Part 1 of this discussion!Content:- What are the practical implications of MRD-testing in myeloma treatment?- How do we think about maintenance therapy in the present day? - What therapies are on the horizon? - How do we approach management of younger patients with relapsed/refractory disease?- How do we approach bridging therapy? ** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows. As a special bonus, one of our guests, Dr. Mohyuddin, is an expert on Primum ready for your questions!** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

In this week's episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly important conversation that is so important in the current treatment landscape and one that you don't want to miss.If you haven't done so already, be sure to check out our CAR T episode.Content:- What are bispecific T-cell engagers? - How are they different than CAR T? - A discussion of the pivotal MajesTEC-3 trial (NEJM 2025) - What are key side effects?- How to sequence CAR T vs. bispecific T-cell engagers? ** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

In this week's episode, we take a practical dive into the relapsed/refractory myeloma space, with a focus on the role of CAR T therapy for relapsed/refractory. In our next episode, we will continue on with a discussion on bispecific agents! This is a conversation that is so important in the current treatment landscape and one that you don't want to miss. Content:- What are treatment options for patients with relapsed/refractory multiple myeloma (R/R MM)? - What is CAR T therapy? And what role does it play in R/R MM?- What are the available options for CAR T for R/R MM?- What are the toxicity profiles of available agents? - How to choose between the options?** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

Chapters:0:00 Intro0:43 Drinking in Japan vs the US8:13 Planning the vlog27:03 Buying the old camcorder and having a nostalgic moment33:22 Returning to the original bar districtFull Vlog - https://www.youtube.com/watch?v=0zN5ri4S66AMy website - https://smallbrainedamerican.tvMy blog - https://smallbrainedamerican.tv/blog/Buy my merch or you're a racist https://www.smallbrainedamerican.storeSupport the show on Patreon to get access to unfiltered travel content. Early access to every video, extended cuts, and uncensored content. https://www.patreon.com/smallbrainedamericanMy gear: DJI Osmo Action 6https://amzn.to/4umNjBQDJI Wireless Mics https://amzn.to/3KkYo4cFollow the show ⬇️ Facebook https://www.facebook.com/realsmallbrainedamericanInstagram https://www.instagram.com/smallbrainedamerican/Twitter https://x.com/SmallBrainedUSAApple Podcasts https://podcasts.apple.com/us/podcast/small-brained-pod/id1724261259

In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including: How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe Practical sequencing decisions after disease progression Emerging BTK degradersas a promising option for heavily pretreated patients Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Matthew S. Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Leader, Lymphoma Program Dana-Farber/Harvard Cancer Center Director of Clinical Research, Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Nelson Hamerschlak, MD, PhD Head of the Department of Hematology, BMT and Clinical Cell Therapy Einstein Hospital Israelita Sao Paulo, Brazil Stephen Stilgenbauer, MD Medical Director, Comprehensive Cancer Center Ulm (CCCU) Head, Early Clinical Trials Unit (ECTU) Head, Division of CLL Department of Internal Medicine III Comprehensive Cancer Center Ulm (CCCU) University of Medical Center Ulm Ulm, Germany Link to the full program: https://bit.ly/4rsZlqF Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

01:07 Good News, Bad News08:14 Pop Trash14:28 Are You Smarter Than A Community College Dropout? 24:19 Voicemail: Mahoney Tries The Big Arch31:30 Redneck Report39:21 Voicemail: Worst Paying Jobs Continued44:06 Shake Shack's Tipping ScandalSocials: @DaveandMahoney Voicemail: 833-Yo-Dummy Additional Content: daveandmahoney.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Featuring an interview with Dr Sagar Lonial, including the following topics: Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00) Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15) Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00) Other investigational strategies for R/R MM (12:55) CME information and select publications

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.

Does emptying the dishwasher feel like climbing Everest? You aren't crazy, and your brain isn't broken. In this video, I explain the 'Dishwasher Theory' of Chronic Fatigue Syndrome and why mundane tasks trigger such extreme crashes—plus, why women might have CFS more often than man. It's time to laugh at the absurdity of the limbic system and your chronic illness. Join the Release program to speed up your healing from ME/CFS, Chronic fatigue, fibromyalgia, MCAS, Post-Vac and other chronic illnesses.

Does emptying the dishwasher feel like climbing Everest? You aren't crazy, and your brain isn't broken. In this video, I explain the 'Dishwasher Theory' of Chronic Fatigue Syndrome and why mundane tasks trigger such extreme crashes—plus, why women might have CFS more often than man. It's time to laugh at the absurdity of the limbic system and your chronic illness. Join the Release program to speed up your healing from ME/CFS, Chronic fatigue, fibromyalgia, MCAS, Post-Vac and other chronic illnesses.

Featuring an interview with Dr Sagar Lonial, including the following topics: KLN-1010: A novel, in vivo gene therapy generating anti-BCMA chimeric antigen receptor T cells (0:00) Phase III DREAMM-7 and DREAMM-8 studies of belantamab mafodotin-based combination therapy for patients with relapsed/refractory (R/R) multiple myeloma (MM) (5:37) Effectiveness of ciltacabtagene autoleucel for patients with R/R MM (11:04) Low-dose tocilizumab for mitigation of the cytokine release syndrome associated with bispecific antibodies (16:04) Talquetamab with teclistamab for patients with R/R MM in Phase Ib of the RedirecTT-1 trial (19:24) CME information and select publications

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.

Featuring perspectives from Dr Sagar Lonial and Dr María-Victoria Mateos, including the following topics:  Introduction (0:00) Best of ASH Multiple Myeloma (1:56) Case: A man in his late 50s with t(11;14) IgA kappa myeloma discovered during workup for new Stage IV kidney disease who has a chest wall plasmacytoma receives daratumumab with CyBorD and radiation therapy to the plasmacytoma with minimal response — Jeremy Lorber, MD (8:35) Antibody-Drug Conjugates and Other Emerging Novel Therapies for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lonial (16:58) Case: A man in his mid 80s with severe obesity and coronary artery disease, chronic heart failure and sleep apnea receives belantamab mafodotin with low-dose pomalidomide for multiregimen-relapsed myeloma — Neil Morganstein, MD (27:57) Case: A man in his mid 60s with a history of stroke with aphasia receives teclistamab for multiregimen-relapsed MM after daratumumab, proteasome inhibitors, immunomodulatory drugs and selinexor — Justin Favaro, MD, PhD (34:42) Integrating Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies into the Management of R/R MM — Dr Mateos (39:09) Case: A man in his early 70s with kappa light chain myeloma experiences complete response on cilta-cel CAR T-cell therapy with hypogammaglobulinemia requiring IVIG and develops melanoma of the abdominal wall — Bhavana (Tina) Bhatnagar, DO (52:07) Case: A man in his mid 50s with heavily relapsed MM who received multiple prior lines of therapy, including CAR T-cell therapy, receives talquetamab — Priya Rudolph, MD, PhD (55:44) CME information and select publications

Dr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting. CME information and select publications here.

In today's episode, the discussion features Lorenzo Falchi, MD, a medical oncologist/hematologist and assistant attending physician in the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, New York, who provided clinical and regulatory perspectives on the FDA approval of epcoritamab-bysp (Epkinly) in combination with rituximab (Rituxan) and lenalidomide (Revlimid) for relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy. The approval was supported by primary results from the randomized phase 3 EPCORE FL-1 trial (NCT05409066).In this exclusive interview, Dr Falchi discussed why this approval is clinically meaningful—establishing a chemotherapy-free triplet that significantly improves outcomes over the long-standing rituximab/lenalidomide backbone in the second-line setting and beyond—and reviewed practical considerations that inform real-world uptake of the regimen, including outpatient administration feasibility and mitigation of bispecific antibody–associated toxicities, such as cytokine release syndrome. He also placed EPCORE FL-1 in the broader epcoritamab development program, referencing supportive experience with the phase 1/2 EPCORE NHL-2 trial (NCT04663347) and ongoing efforts to move bispecific antibody–based regimens earlier in the treatment paradigm through the phase 3 EPCORE FL-2 trial (NCT06191744).any of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Andrew Grazen shares his journey from a seemingly normal childhood into years of addiction, incarceration, and near-death experiences, and how recovery, community, and writing ultimately saved his life. From discovering substances at a young age to overdosing in his car and writing a memoir while incarcerated, Andrew reflects on loss, resilience, and why staying connected—and holding onto hope—can change everything. ----Across the Web----

In today's episode, the discussion features Surbhi Sidana, MD, an associate professor of medicine (blood and marrow transplantation and cellular therapy) and leader of the Myeloma CAR-T/Immunotherapy Program at Stanford University/Stanford Medicine, as well as a member of the Stanford Cancer Institute, who provided clinical and regulatory perspectives on the FDA approval of belantamab mafodotin-blmf (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval was supported by findings from the phase 3 DREAMM-7 trial (NCT04246047).

Relapse and Relapse Prevention for Overeating Featuring Dr. Angela Krumm On today's podcast, we proudly feature an old friend, Dr. Angela Krumm, on the topic of relapse prevention for habits and addictions. This is certainly a top of incredible importance, since all treatments for all habits and addictions seem to have extremely high relapse rates. Anything we could do to reduce that would be a major contribution. Angela was on our Feeling Good Podcast #270 on Nov 29, 2021 describing some TEAM CBT methods she'd developed to deal with her own weight gain. In podcast #270 she taught listeners how to set process goals, instead of outcome focused goals. She then taught about the Triple Paradox, Habit Addiction Log, Devil's Advocate technique, and the Problem-Solution log. In that first episode she explained that this was a difficult time in her life: her father had died, and she'd also experienced a traumatic fall which caused a concussion. So she fell off being careful about her diet, and one day was shocked that she could not recognize herself—due to weight gain--in a photo, and was on the fast track to Type II Diabetes. As a result, she utilized many of the TEAM CBT techniques and slowly, but surely, lost weight and kept it off for multiple years. She explains that she was "solid for a long time, but have to confess, with shame, that I eventually relapsed because I got over-confident. I'd been tracking what I ate, which was an important key for me, and stopped keeping up with it consistently, thinking I didn't really need to anymore." We reviewed the kinds of tempting thoughts she'd had (and still has, of course, at times), when she feels tempted by her favorites: things like delicious brownies, red wine, and other sweet treats.  She has tempting thoughts such as: I deserve to take a break from tracking what I eat. I deserve a treat—I've had a hard day. It's silly to be so rigid. I deserve to eat whatever I want. Spontaneity is one of my core values! During the podcast, we illustrated the Devil's Advocate Technique (DAT), which is powerful and a lot of fun, but sometimes trickier than it looks. When Angela gave a "good" but not "huge" response to one of these tempting thoughts, I automatically suggested a role-reversal. Rhonda immediately and rightly reminded us that we never do role-reversals when people are stuck during the Devil's Advocate. Instead, we paradox the person and sit with open hands. Rhonda modeled this beautifully and it worked like a charm. Angela had a sudden about face and blew the tempting thought out of the water immediately. We made three teaching points on DAT. Don't give in to the urge to "help." This will have the opposite effect of keeping the patient stuck. Realize that if you're a therapist, and your patient cannot convincingly defeat all the temping thoughts in the office, the likelihood that they can defeat them when they're at home is 0%. So, the DAT is both a powerful technique to boost motivation with tools you can use when tempted, but it is also a powerful test of motivation. Remember to Sit with Open Hands if your patients cannot convincingly defeat their tempting thoughts. Angela shared that she now realizes that the main reason for her relapse was that she had skipped relapse prevention. This is the danger of being your own therapist, sometimes you make the mistake of cutting corners or getting overly confident. She asked to return to the podcast today to talk about that important mistake and help others prevent that mistake in the future. She wants us to emphasize the important of Relapse Prevention for all habits and addictions. When Angela mentioned that she'd relapsed in her eating to a therapist who was just learning TEAM-CBT, the therapist seemed shocked and asked, "Oh, does this mean that the techniques we're learning don't actually work?" This is such a great (but naïve and common) question, because we always emphasize that all patients—in fact all human beings—will relapse after recovery from depression, anxiety, a relationship conflict, or a habit / addiction. That's why it's so important to tell patients about relapse before discharge from therapy, and do a brief but intensive relapse prevention intervention. We reviewed several of the Relapse Prevention techniques, including the Problem Solution List and the Relapse Prevention Daily Mood Log, using and recording the Externalization of Voices. When you do this step with a patient, ask them to imagine the future moment in time when they have relapsed. It's important to capture the thoughts that will lead them to give up and quit using the techniques. Often, these are hopeless thoughts about the usefulness of the techniques or their ability to remain in recovery. If these thoughts are left unchecked, they will spiral the person into a deeper and more lengthy relapse. If they can predict the thoughts ahead of time and generate powerful rebuttals to use in that moment, then their first moment of relapse can be turned around quickly! We listed several of Angela's predicted negative thoughts during her relapse: I should not have let this happen. 100% I'm not strong enough. 60% It's just too hard to start tracking and logging what I eat again. 65% It will be too painful to have to track and see what I've eaten. 60% This isn't fair. It should be so hard to be healthy! 70% Screw it. I should just accept this and give up! 40% Podcast listeners will judge me because I have gained weight again. 10% We practiced challenging those thoughts with the Externalization of Voices, and Rhonda summarize several of the strategies that can be the most helpful: Self-Defense The Acceptance Paradox. The Counter-Attack Technique A combination of two or three Angela summarized three important take home messages from today's podcast. Always prepare a Relapse Daily Mood Log ahead of time, anticipating what you will be telling yourself when you relapse Challenge those thoughts with EOV and record that role-play so you can listen to it in the future when tempted. After you have lost sufficient weight, make a plan to continue your healthier eating after the acute phase. Do NOT make the common mistake of thinking, "Oh, I've achieved my goal of losing 30 pounds (or whatever), so now I'm done, and can go back to my normal eating habits and patterns again." Thank you for listening today! Angela, Rhonda, and David

Relapsed/refractory follicular lymphoma (R/R FL) is challenging to treat, requiring thoughtful clinical decision-making during treatment selection and sequencing. In this episode, CANCER BUZZ speaks with Benjamin Heyman, MD, hematologist and clinical associate professor at City of Hope, about the importance of individualized care, shared decision-making, clinical trial referrals, and multidisciplinary collaboration. CANCER BUZZ also speaks with Laurie Adami, patient advocate with R/R FL, about her real-world experience with multiple lines of therapy, clinical trials, and patient advocacy.     "There are lots of options available, which is really great for patients, so you get to have a good conversation with patients about what they value." - Benjamin Heyman, MD   "The medications you receive in clinical trials may not be the standard of care today, but it may be the standard of care 5 years from now." - Benjamin Heyman, MD   "Patient advocacy organizations have patients that can talk to you. They know what you're talking about. They're on the road ahead of you." - Laurie Adami   Guest:                    Benjamin Heyman, MD Hematologist Clinical Associate Professor City of Hope San Diego, CA   Laurie Adami R/R FL Patient Advocate Los Angeles, LA Received care at UCLA Lymphoma Program   Additional Reading/Sources ACCC Follicular Lymphoma Effective Practice Guide: Multidisciplinary Approaches to Treating Patients With R/R FL Putting Guidance Into Practice: Real-World Approaches to Relapsed/Refractory Folicular Lymphoma ACCC's Community Oncology Research Institute

Featuring perspectives from Dr Matthew Lunning and Dr Sonali M Smith, including the following topics:  Which Driver and Which Race: CAR-T and Bispecific Antibodies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr Lunning (0:00) Available and Emerging Novel Therapies for Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr Smith (32:37) CE information and select publications

T. Hack has been holding onto junk for way too long...until he found a use to justify it!

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents:- What are "CAR T" and "bispecific antibodies"?- What are the approved agents?- Selection of one therapy over another- Side effect profiles**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast